A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
- PMID: 17922221
- DOI: 10.1007/s11136-007-9270-9
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
Abstract
Objective: To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI).
Methods: Ninety-eight patients with head and neck cancer were randomized to one of two assessment conditions to evaluate the FHNSI's context (items administered embedded within the FACT-H&N or as stand-alone scale) and order of administration in the battery.
Results: Planned comparisons on the item and scale levels revealed no systematic order or context differences. The embedded and stand-alone versions of the FHNSI showed high internal consistency (Cronbach's alpha 0.79-0.87). Correlations were high between the FHNSI versions and the physical and functional well-being scales of the FACT-H&N (0.70-0.84) and measures of pain intensity (-0.73, -0.74) and depression (-0.71, -0.74); moderate to large with the Performance Status Scale for Head and Neck subscales (PSS-HN; 0.46-0.71); and low with an anxiety measure (0.30, 0.34). Both FHNSI versions differentiated patients grouped by performance status (p < .0001, p < .0001) and global rating of change (p < .0001, p < 0.01). The FHNSI's minimally important difference range was 3-4 points.
Conclusion: The FHNSI is a reliable and valid symptom index, which can be administered alone or scored using items embedded within the FACT-H&N.
Similar articles
-
Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer.Support Care Cancer. 2024 Aug 6;32(9):575. doi: 10.1007/s00520-024-08775-x. Support Care Cancer. 2024. PMID: 39107440
-
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302).Cancer Med. 2020 Dec;9(23):8884-8894. doi: 10.1002/cam4.3506. Epub 2020 Oct 10. Cancer Med. 2020. PMID: 33040481 Free PMC article. Clinical Trial.
-
The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity.Cancer. 1996 Jun 1;77(11):2294-301. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S. Cancer. 1996. PMID: 8635098
-
Supportive care among head and neck cancer patients: An initial validation of the Dutch version of the Performance Status Scale for Head and Neck Cancer (D-PSS-HN).Int J Lang Commun Disord. 2023 Sep-Oct;58(5):1668-1679. doi: 10.1111/1460-6984.12894. Epub 2023 May 15. Int J Lang Commun Disord. 2023. PMID: 37189297
-
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699. doi: 10.1016/j.ijrobp.2016.08.003. Epub 2016 Aug 12. Int J Radiat Oncol Biol Phys. 2017. PMID: 27727066 Free PMC article. Clinical Trial.
Cited by
-
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.Qual Life Res. 2024 Apr;33(4):1075-1084. doi: 10.1007/s11136-023-03587-8. Epub 2024 Jan 24. Qual Life Res. 2024. PMID: 38265747 Free PMC article.
-
Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10).Health Sci Rep. 2021 Oct 19;4(4):e401. doi: 10.1002/hsr2.401. eCollection 2021 Dec. Health Sci Rep. 2021. PMID: 34708159 Free PMC article.
-
Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer.Support Care Cancer. 2024 Aug 6;32(9):575. doi: 10.1007/s00520-024-08775-x. Support Care Cancer. 2024. PMID: 39107440
-
Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review.World J Oncol. 2013 Feb;4(1):8-17. doi: 10.4021/wjon594w. Epub 2013 Mar 6. World J Oncol. 2013. PMID: 29147325 Free PMC article. Review.
-
The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer.Support Care Cancer. 2019 Dec;27(12):4627-4637. doi: 10.1007/s00520-019-04748-7. Epub 2019 Apr 2. Support Care Cancer. 2019. PMID: 30941580 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical